Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

IGF-1 LR3 and TB-500 Interaction: Synergistic | Peptide Database

Can you take IGF-1 LR3 with TB-500? Synergistic interaction (95% confidence). See pharmacological analysis, organ load, safety flags, and dosing guidance.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Compound Profiles

IGF-1 LR3

Modified Growth Factor Analog | Muscle Growth

Functions as a full IGF-1 receptor agonist activating PI3K/Akt/mTOR and MAPK/ERK pathways. The modifications prevent protein sequestration, maintaining elevated free circulating levels for extended anabolic effects.

TB-500

Synthetic Fragment (17-23) of Thymosin Beta-4

Acts as principal actin-sequestering protein, regulating cell migration, promoting angiogenesis, reducing inflammation, and activating stem cell differentiation for comprehensive regenerative effects..

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take IGF-1 LR3 with TB-500?

Yes, IGF-1 LR3 and TB-500 can generally be taken together. Different repair pathway activation.

Is IGF-1 LR3 and TB-500 safe together?

Based on documented research, this combination is considered synergistic. However, shared safety flags include: carcinogenic risk. Monitor accordingly.

What are the interactions between IGF-1 LR3 and TB-500?

Different repair pathway activation. This assessment has 95% confidence and is based on documented research data.

How should I time IGF-1 LR3 and TB-500?

IGF-1 LR3 has a half-life of 20-30 hours and TB-500 has a half-life of ~2 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.

Connected topics

Follow this recovery question